Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR10900562

—

9ef96b01-826f-5976-bdbe-d7783d8e1a0d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.400
  • INTERFERON_GAMMA_RESPONSE+0.400
  • MYC_TARGETS_V2+0.400
  • ALLOGRAFT_REJECTION+0.300
  • E2F_TARGETS+0.300
  • APICAL_SURFACE+0.200
  • G2M_CHECKPOINT+0.200
  • INFLAMMATORY_RESPONSE+0.200
  • P53_PATHWAY+0.200
  • PANCREAS_BETA_CELLS+0.200

Top 10 suppressed

  • PROTEIN_SECRETION-0.500
  • ANGIOGENESIS-0.400
  • ANDROGEN_RESPONSE-0.300
  • OXIDATIVE_PHOSPHORYLATION-0.300
  • UV_RESPONSE_DN-0.300
  • ADIPOGENESIS-0.200
  • CHOLESTEROL_HOMEOSTASIS-0.200
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
  • MTORC1_SIGNALING-0.200
  • TGF_BETA_SIGNALING-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1AUR-AFR5-TTP1-A-1-1-R-A743-41
breast-umap@18
—D0.823
2c4779698-5c81-4eed-80ac-80fdd47f658b
colon-landscapes@1
——0.798
3SRR8613767
breast-umap@18
—E0.788
4e5c23a09-dd5f-4eda-8eca-f4aea9b71c20
colon-landscapes@1
——0.736
5TCGA-B6-A0I2-01A-11R-A034-07
breast-umap@18
—E0.730
6SRR8613797
breast-umap@18
—D0.728
720030081.TNBC
breast-umap@18
—D0.722
8SRR12475104
colon-landscapes@1
——0.720
9TCGA-BH-A18V-06A-11R-A213-07
breast-umap@18
—D0.719
10SRR8518357
breast-umap@18
—D0.712

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.400Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.400Idelalisib— uncovered
MYC_TARGETS_V20.400Idelalisib— uncovered
ALLOGRAFT_REJECTION0.300Idelalisib— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
APICAL_SURFACE0.200Temsirolimus— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.200Idelalisib— uncovered
P53_PATHWAY0.200Idelalisib— uncovered
PANCREAS_BETA_CELLS0.200Cobimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.200Inavolisib— uncovered
UV_RESPONSE_UP0.200Idelalisib— uncovered
APOPTOSIS0.100Idelalisib— uncovered
COAGULATION0.100Binimetinib— uncovered
COMPLEMENT0.100Inavolisib— uncovered
DNA_REPAIR0.100Idelalisib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
IL2_STAT5_SIGNALING0.100Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.100Inavolisib— uncovered
KRAS_SIGNALING_DN0.100Remibrutinib— uncovered